Criteria Capital Risc
Wholly owned venture capital management company of CriteriaCaixa
Also known as Caixa Capital Risc, Caixa Capital Risc, SGEIC, S.A., CCR
Barcelona venture capital arm of CriteriaCaixa, founded 2002 as Caixa Capital Risc and renamed in 2026; invests through Criteria Venture Tech and Criteria Bio Ventures.
- HEADQUARTERS
- Barcelona, Spain
- FOUNDED
- 2002
- AUM
- —
- OUTSIDE CAPITAL
- No — own capital only
- TEAM LISTED
- 10 people
Focus
- STAGES
- Pre-SeedSeedSeries ASeries BGrowth
- ASSET MIX
- Venture capital
- GEOGRAPHY
- SpainPortugalEuropeNorth America
Investment arms & vehicles
- Technology fund focused on deep tech, AI, cybersecurity and software and data infrastructure, from pre-seed and seed
- Evergreen life sciences venture vehicle backing private biotech companies in Europe and North America, with a focus on Spain and Portugal
Overview
Criteria Capital Risc was founded in 2002 within ”la Caixa” as Caixa Capital Risc and became a wholly owned subsidiary of CriteriaCaixa in 2013; it adopted its current name in July 2026. It invests CriteriaCaixa’s capital in early-stage science and technology companies through two vehicles, Criteria Venture Tech and Criteria Bio Ventures, which plan to invest €300m under CriteriaCaixa’s 2030 Strategic Plan, mainly in Spain and Portugal. It sits within CriteriaCaixa’s alternative investment portfolio.
Investment thesis
Criteria Venture Tech leads or co-leads pre-seed and seed rounds in deep tech, AI, cybersecurity and software/data infrastructure; Criteria Bio Ventures backs biotech companies with new therapies for unmet medical needs, across modalities, from early to growth stages.
PORTFOLIO (12)
- Minoryx TherapeuticsNOTABLEBiotech & Life Sciences
- iPronicsNOTABLEDeep Tech
- vLexNOTABLESoftware & SaaS · Acquired (Clio)
- Adaptam TherapeuticsBiotech & Life Sciences
- Aboleris PharmaBiotech & Life Sciences
- NRG TherapeuticsBiotech & Life Sciences
- Tolerance BioBiotech & Life Sciences
- Cytospire TherapeuticsBiotech & Life Sciences
- ImmflySoftware & SaaS
- BarbaraSoftware & SaaS
- 8LayersSoftware & SaaS · since 2026
- Sanifit TherapeuticsBiotech & Life Sciences · Acquired (Vifor Pharma)
People
- Roma JelinskaiteManaging Director, Criteria Venture Tech · source
- Milós EstevaPortfolio Manager, Criteria Venture Tech · source
- Albert MorroPrincipal, Criteria Venture Tech · source
- Aleix PérezPrincipal, Criteria Venture Tech · source
- Pablo CironiInvestment Director, Criteria Bio Ventures · source
- Salvatore CappadonaPrincipal, Criteria Bio Ventures · source
- Sebastián ChiavennaPrincipal, Criteria Bio Ventures · source
- Alejo ChornyPrincipal, Criteria Bio Ventures · source
- Juan-Pablo BartraFinance Operations Manager · source
- Beltrán VivesIn-house lawyer / Legal Counsel · source
Links
Frequently asked questions
Criteria Capital Risc is a corporate venture arm based in Barcelona, Spain, founded in 2002.
Yes. Criteria Capital Risc invests its own capital in private companies.
Criteria Capital Risc invests at Pre-Seed, Seed, Series A, Series B and Growth stages in Deep Tech, Artificial Intelligence, Software & SaaS, Biotech & Life Sciences and HealthTech.
Criteria Capital Risc's stated ticket size is €500K–€5M.
Key people at Criteria Capital Risc include Roma Jelinskaite (Managing Director, Criteria Venture Tech), Milós Esteva (Portfolio Manager, Criteria Venture Tech), Albert Morro (Principal, Criteria Venture Tech) and Aleix Pérez (Principal, Criteria Venture Tech).
Criteria Capital Risc's investments include Minoryx Therapeutics, iPronics, vLex, Adaptam Therapeutics, Aboleris Pharma, NRG Therapeutics, Tolerance Bio and Cytospire Therapeutics, among others.
The most recent publicly reported investment by Criteria Capital Risc is 8Layers (Pre-seed extension to €2.5m, led by Criteria Venture Tech), announced in Jul 2026.
Criteria Capital Risc states that it accepts submissions through its official contact page.
No. Criteria Capital Risc invests its own capital and does not raise money from outside investors.